Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 6.16% and Operating profit at -15.29% over the last 5 years
2
The company has declared Negative results for the last 3 consecutive quarters
3
With ROE of 5.51%, it has a expensive valuation with a 4.06 Price to Book Value
4
Market Beating Performance
Stock DNA
Pharmaceuticals & Biotechnology
CNY 7,469 Million (Mid Cap)
74.00
NA
0.16%
-0.18
5.51%
4.06
Revenue and Profits:
Net Sales:
372 Million
(Quarterly Results - Jun 2025)
Net Profit:
25 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-17.97%
0%
-17.97%
6 Months
15.21%
0%
15.21%
1 Year
64.51%
0%
64.51%
2 Years
36.83%
0%
36.83%
3 Years
82.87%
0%
82.87%
4 Years
78.06%
0%
78.06%
5 Years
0%
0%
0.0%
Hunan Warrant Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
6.16%
EBIT Growth (5y)
-15.29%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.08
Sales to Capital Employed (avg)
0.75
Tax Ratio
11.03%
Dividend Payout Ratio
24.46%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
16.36%
ROE (avg)
12.38%
Valuation key factors
Factor
Value
P/E Ratio
74
Industry P/E
Price to Book Value
4.06
EV to EBIT
78.28
EV to EBITDA
42.57
EV to Capital Employed
4.72
EV to Sales
5.23
PEG Ratio
NA
Dividend Yield
0.16%
ROCE (Latest)
6.03%
ROE (Latest)
5.51%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
372.30
357.30
4.20%
Operating Profit (PBDIT) excl Other Income
42.80
66.80
-35.93%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
24.90
46.80
-46.79%
Operating Profit Margin (Excl OI)
62.00%
137.90%
-7.59%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 4.20% vs -0.78% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -46.79% vs -20.14% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,387.20
1,413.50
-1.86%
Operating Profit (PBDIT) excl Other Income
204.50
265.10
-22.86%
Interest
0.30
0.10
200.00%
Exceptional Items
0.00
-5.30
100.00%
Consolidate Net Profit
138.80
193.00
-28.08%
Operating Profit Margin (Excl OI)
95.50%
143.40%
-4.79%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -1.86% vs 10.79% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -28.08% vs 11.30% in Dec 2023
About Hunan Warrant Pharmaceutical Co., Ltd. 
Hunan Warrant Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






